Article
Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Breast cancer research and treatment - 1 Dec 2009
Dieudonné A S, Lambrechts D, Claes B, Vandorpe T, Wildiers H, Timmerman D, Billen J, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Weltens C, Van Limbergen E, Van den Bogaert W, Vergote I, Van Huffel S, Christiaens M R, Neven P
Abstract excerpt
Retrospective studies suggest that single nucleotide polymorphisms in the cytochrome P450 2D6 (CYP2D6) gene predict reduced tamoxifen metabolism, better tolerance and worse treatment outcome. We hypothesized that women with this genotype lack tamoxifen-induced endometrial and biochemical changes in follicle-stimulating hormone (FSH) and sex hormone-binding globulin (SHBG). We identified 56 breast cancer patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.